tirzepatide 2023788-19-2 china factory high purity 99.8%
Tirzepatide is a synthetic compound derived from gastric inhibitory polypeptide (GIP), with the added functionality of glucagon-like peptide-1 (GLP-1). By combining these properties, Tirzepatide effectively reduces blood glucose levels, improves insulin sensitivity, enhances satiety, and promotes weight loss. While originally developed as a treatment for type 2 diabetes, Tirzepatide has also demonstrated the ability to protect the cardiovascular system and act as a potent agent for weight reduction. Tirzepatide belongs to a class of medications called glucagon-like peptide-1 receptor agonist (GLP-1 RA) and glucagon receptor agonist (GRA) dual agonists. Tirzepatide is being developed for the treatment of type 2 diabetes mellitus. GLP-1 RA drugs work by increasing the secretion of insulin, which helps lower blood sugar levels, and by reducing the production of glucagon, which helps prevent the liver from releasing excess glucose into the bloodstream. GRA drugs, on the other hand, work by decreasing the levels of glucagon, which can help reduce blood sugar levels. The combination of GLP-1 RA and GRA properties in tirzepatide aims to provide more effective blood sugar control compared to individual medications. It is also believed to promote weight loss and may have additional benefits such as cardiovascular risk reduction.
Tirzepatide is a synthetic compound derived from gastric inhibitory polypeptide (GIP), with the added functionality of glucagon-like peptide-1 (GLP-1). By combining these properties, Tirzepatide effectively reduces blood glucose levels, improves insulin sensitivity, enhances satiety, and promotes weight loss. While originally developed as a treatment for type 2 diabetes, Tirzepatide has also demonstrated the ability to protect the cardiovascular system and act as a potent agent for weight reduction.Tirzepatide belongs to a class of medications called glucagon-like peptide-1 receptor agonist (GLP-1 RA) and glucagon receptor agonist (GRA) dual agonists.
Tirzepatide is being developed for the treatment of type 2 diabetes mellitus. GLP-1 RA drugs work by increasing the secretion of insulin, which helps lower blood sugar levels, and by reducing the production of glucagon, which helps prevent the liver from releasing excess glucose into the bloodstream. GRA drugs, on the other hand, work by decreasing the levels of glucagon, which can help reduce blood sugar levels.
The combination of GLP-1 RA and GRA properties in tirzepatide aims to provide more effective blood sugar control compared to individual medications. It is also believed to promote weight loss and may have additional benefits such as cardiovascular risk reduction.
